Multiple Myeloma

10 protocols meet the specified criteria.

• 68284528MMY4006

  Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

• A151804

  Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events

• A211901

  Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions

• BB2121-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

• EAA173

  Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma

• EAY191

  Molecular Analysis for Combination Therapy Choice (ComboMATCH)

• GRAIL-MA-002

  REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)

• JCAR017-EAP-001

  Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release

• KT-US-472-0141

  Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication

• WVU010922

  Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia